Agreements reached under this partnership
Licensing Agreements- 1
Acquisition of the exclusive development rights to MHB018A in Japan
- 2
Acquisition of the exclusive marketing rights to MHB018A in Japan
- 3
Payment of the upfront fee
- 4
Payment of milestones based on development progress and sales
- 5
Payment of royalties based on sales
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact on consolidated results for the fiscal year ending March 2027 will be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | Minghui Pharmaceutical (Hangzhou) Limited |
| Alliance partner's business activities | A late-stage biopharmaceutical company engaged in the development of innovative treatments in immunology, oncology and other areas with high unmet medical needs |
| Alliance partner's location | Hangzhou, China |
| Type of alliance | Licensing Agreements |
| Details of the alliance | Acquisition of the exclusive development rights to MHB018A in Japan, Acquisition of the exclusive marketing rights to MHB018A in Japan, Payment of the upfront fee, Payment of milestones based on development progress and sales, Payment of royalties based on sales |
| Date of board resolution | 4 November 2026 |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 will be immaterial. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the thyroid and specialty areas, expand the product lineup, and provide a new treatment option in Japan for patients with thyroid eye disease, for whom treatment options are limited.